https://www.andorrahealthwatch.com/article/905824743-ose-immunotherapeutics-to-present-a-novel-first-in-class-fpr2-agonist-monoclonal-antibody-in-the-resolution-of-chronic-inflammation-at-the-aai-2026 Andorra Health Watch en PressRelease 2026-04-15T05:30:00+00:00 OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ose-logo-horizontal-rvb-png.png https://www.andorrahealthwatch.com/article/905824755-ose-immunotherapeutics-pr-sentera-un-nouvel-anticorps-monoclonal-first-in-class-agoniste-de-fpr2-dans-la-r-solution-de-l-inflammation-chronique-au Andorra Health Watch en PressRelease 2026-04-15T05:30:00+00:00 OSE Immunotherapeutics présentera un nouvel anticorps monoclonal, first-in-class, agoniste de FPR2 dans la résolution de l’inflammation chronique au Congrès 2026 de l’AAI https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ https://www.andorrahealthwatch.com/article/905824846-bioversys-to-present-data-on-clinical-and-preclinical-pipeline-programs-at-escmid-global-2026 Andorra Health Watch en PressRelease 2026-04-15T05:00:00+00:00 BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026 https://ml.globenewswire.com/media/37dee549-5eb0-418f-a16c-11d8422babfb/small/logo-bioversys-color-rgb-neu-for-prs-jpg.jpg https://www.andorrahealthwatch.com/article/905824961-revolution-medicines-inc-prices-2-0-billion-in-concurrent-upsized-offerings-of-common-stock-and-convertible-senior-notes Andorra Health Watch en PressRelease 2026-04-15T04:41:13+00:00 Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes https://ml.globenewswire.com/media/771b34d9-586d-435a-a976-ab0ab847571b/small/balanced-green-primary-logo-medium-1000px-png.png https://www.andorrahealthwatch.com/article/905808332-spyre-therapeutics-announces-pricing-of-upsized-403-0-million-public-offering-of-common-stock Andorra Health Watch en PressRelease 2026-04-15T02:38:25+00:00 Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock https://ml.globenewswire.com/media/bc26a912-b583-43c6-8423-55a4ba2bf4bd/small/spyre-logo-horizontal-full-color-rgb-583px-300ppi-jpg.jpg https://www.andorrahealthwatch.com/article/905808311-lecom-makes-pharmacy-education-more-accessible-with-three-fully-accredited-doctor-of-pharmacy-pathways Andorra Health Watch en PressRelease 2026-04-15T02:31:27+00:00 LECOM Makes Pharmacy Education More Accessible with Three Fully Accredited Doctor of Pharmacy Pathways https://ml.globenewswire.com/Resource/Download/53969c12-c282-4b1a-a914-4ac7480a61e3/image1.jpeg https://www.andorrahealthwatch.com/article/905790975-allogene-therapeutics-announces-pricing-of-public-offering-of-common-stock Andorra Health Watch en PressRelease 2026-04-15T01:50:00+00:00 Allogene Therapeutics Announces Pricing of Public Offering of Common Stock https://ml.globenewswire.com/media/87e8712c-0741-409f-9942-c91b31e7c5e1/small/allogene-png.png https://www.andorrahealthwatch.com/article/905790950-american-addiction-centers-and-filmmaker-jeffrey-shulman-team-up-to-promote-powerful-new-film-on-addiction-and-recovery-with-national-theatrical-tour Andorra Health Watch en PressRelease 2026-04-15T01:17:26+00:00 American Addiction Centers and Filmmaker Jeffrey Shulman Team Up to Promote Powerful New Film on Addiction and Recovery with National Theatrical Tour https://ml.globenewswire.com/media/1cd36806-58ee-4d6f-935f-bd2088746d5d/medium/what-it-takes-official-film-poster.JPG https://www.andorrahealthwatch.com/article/905790908-arc-trt-launches-new-website-to-help-uk-men-access-personalised-testosterone-replacement-therapy Andorra Health Watch en PressRelease 2026-04-15T01:03:33+00:00 Arc TRT Launches New Website to Help UK Men Access Personalised Testosterone Replacement Therapy https://ml.globenewswire.com/media/adfa345c-868c-4bca-bdda-15d2ab4d6315/small/arc-trt-png.png https://www.andorrahealthwatch.com/article/905791055-epimab-biotherapeutics-to-present-a-novel-prodrug-t-cell-engager-protce-platform-at-the-2026-american-association-for-cancer-research-annual-meeting Andorra Health Watch en PressRelease 2026-04-15T01:00:00+00:00 EpimAb Biotherapeutics to Present a Novel Prodrug T-Cell Engager (ProTCE) Platform at the 2026 American Association for Cancer Research Annual Meeting https://ml.globenewswire.com/media/fa1bd13e-e49a-4b2c-a742-85957a03ad87/small/epimab-logo-for-notified-png.png https://www.andorrahealthwatch.com/article/905776369-mesoblast-acquires-chimeric-antigen-receptor-car-platform-technology-for-precision-enhanced-cell-products Andorra Health Watch en PressRelease 2026-04-15T00:10:56+00:00 Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products https://ml.globenewswire.com/media/a9938a8a-a0ba-4708-abd5-2219515343fc/small/mesologo-png.png https://www.andorrahealthwatch.com/article/905776367-telix-doses-first-patient-in-phase-3-ipax-bright-trial-of-tlx101-tx-for-recurrent-glioblastoma Andorra Health Watch en PressRelease 2026-04-14T23:04:43+00:00 Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png https://www.andorrahealthwatch.com/article/905763136-bruno-mars-presents-1-million-gift-to-intermountain-health-for-the-future-nevada-children-s-hospital Andorra Health Watch en PressRelease 2026-04-14T21:40:23+00:00 Bruno Mars Presents $1 Million Gift to Intermountain Health for the Future Nevada Children’s Hospital https://ml.globenewswire.com/media/OGZmZTRlNzItNGMwOS00NDY4LWJlNzgtZGRiNjk5Mjc4ODU1LTEyNjkxMjYtMjAyNi0wNC0xNC1lbg==/tiny/Intermountain-Health.png https://www.andorrahealthwatch.com/article/905763051-lymph-tonic-claims-evaluated-the-forbidden-enzyme-protocol-for-safe-weight-loss-support-by-lymphtonic Andorra Health Watch en PressRelease 2026-04-14T21:37:48+00:00 Lymph Tonic Claims Evaluated: The Forbidden Enzyme Protocol for Safe Weight Loss Support by LymphTonic https://zingfast.com/wp-content/uploads/2026/04/Lymph-Tonic.jpg https://www.andorrahealthwatch.com/article/905762991-enlitic-announces-ensight-2-2-a-breakthrough-in-imaging-data-standardization Andorra Health Watch en PressRelease 2026-04-14T21:29:27+00:00 Enlitic Announces Ensight 2.2, a Breakthrough in Imaging Data Standardization https://ml.globenewswire.com/media/372da620-5254-4763-8d1e-53195694c648/medium/enlitic-announces-ensight-2-2-a-breakthrough-in-imaging-data.jpg https://www.andorrahealthwatch.com/article/905750683-lemaitre-will-announce-first-quarter-2026-earnings-results-on-may-5-2026 Andorra Health Watch en PressRelease 2026-04-14T20:54:05+00:00 LeMaitre Will Announce First Quarter 2026 Earnings Results on May 5, 2026 https://ml.globenewswire.com/media/8b8755b7-6f04-4650-9c94-0a2d0654fd49/small/lemaitre-2color-rgb-jpg.jpg https://www.andorrahealthwatch.com/article/905749724-ankalax-claims-evaluated-effective-ankle-massager-brace-with-heat-therapy-vibration-compression-for-recovery Andorra Health Watch en PressRelease 2026-04-14T20:28:01+00:00 Ankalax Claims Evaluated: Effective Ankle Massager Brace with Heat Therapy + Vibration Compression for Recovery https://zingfast.com/wp-content/uploads/2026/04/Ankalax-Ankle-Massage-Brace.jpg https://www.andorrahealthwatch.com/article/905749617-update-r1-announces-phare-os-expansion-to-help-providers-navigate-growing-complexity-and-margin-pressure Andorra Health Watch en PressRelease 2026-04-14T20:25:34+00:00 UPDATE - R1 Announces Phare OS Expansion to Help Providers Navigate Growing Complexity and Margin Pressure https://ml.globenewswire.com/media/728189a4-e254-443f-8452-315403fd70f4/small/r1-logo-black-25-947x676-jpg.jpg https://www.andorrahealthwatch.com/article/905748202-heartsciences-reminds-its-shareholders-to-submit-their-vote-at-the-upcoming-april-30-2026-annual-shareholders-meeting Andorra Health Watch en PressRelease 2026-04-14T20:15:00+00:00 HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting https://ml.globenewswire.com/media/800a6aae-74f3-42bb-9199-5e169ed9b881/small/heartsciences-png.png https://www.andorrahealthwatch.com/article/905748222-aligos-therapeutics-announces-first-interim-analysis-results-from-the-phase-2-b-supreme-study-of-pevifoscorvir-sodium-in-participants-with-chronic Andorra Health Watch en PressRelease 2026-04-14T20:05:00+00:00 Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation https://ml.globenewswire.com/media/03ffbe89-c47f-4f83-b51f-f13a572e2cd1/small/aligos-png.png https://www.andorrahealthwatch.com/article/905748406-structure-therapeutics-appoints-matthew-lang-j-d-as-chief-operating-officer-and-general-counsel Andorra Health Watch en PressRelease 2026-04-14T20:05:00+00:00 Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel https://ml.globenewswire.com/media/154be1d7-62d7-4688-be20-3b2a10a2628e/small/structure-therapeutics-png.png https://www.andorrahealthwatch.com/article/905748488-geron-corporation-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4 Andorra Health Watch en PressRelease 2026-04-14T20:05:00+00:00 Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/e184bb51-5636-436e-8964-15613f24ca1f/small/geron-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905748979-canadian-animal-health-institute-unleashes-cutest-pets-on-parliament-hill Andorra Health Watch en PressRelease 2026-04-14T20:00:00+00:00 Canadian Animal Health Institute Unleashes Cutest Pets on Parliament Hill  https://ml.globenewswire.com/media/197c2953-84e0-435d-8524-c68da19d27e9/small/cahi-logo-jpg.JPG https://www.andorrahealthwatch.com/article/905748980-l-institut-canadien-de-la-sant-animale-lib-re-les-animaux-de-compagnie-les-plus-mignons-sur-la-colline-du-parlement Andorra Health Watch en PressRelease 2026-04-14T20:00:00+00:00 L’Institut canadien de la santé animale libère les animaux de compagnie les plus mignons sur la Colline du Parlement  https://ml.globenewswire.com/media/197c2953-84e0-435d-8524-c68da19d27e9/small/cahi-logo-jpg.JPG https://www.andorrahealthwatch.com/article/905736235-national-roundtable-advances-women-s-health-and-chronic-pain-research-in-canada Andorra Health Watch en PressRelease 2026-04-14T19:17:30+00:00 National Roundtable Advances Women’s Health and Chronic Pain Research in Canada https://ml.globenewswire.com/media/32c18902-bbfd-4447-afb8-37712906af67/small/centre-of-excellence-logo-png.png https://www.andorrahealthwatch.com/article/905736758-la-table-ronde-nationale-fait-progresser-les-recherches-sur-la-sant-et-la-douleur-chronique-au-canada Andorra Health Watch en PressRelease 2026-04-14T19:17:30+00:00 La table ronde nationale fait progresser les recherches sur la santé et la douleur chronique au Canada https://ml.globenewswire.com/media/32c18902-bbfd-4447-afb8-37712906af67/small/centre-of-excellence-logo-png.png https://www.andorrahealthwatch.com/article/905736407-dr-eric-haeger-establishes-new-scholarship-program-to-support-future-medical-professionals-and-healthcare-innovation Andorra Health Watch en PressRelease 2026-04-14T19:07:19+00:00 Dr. Eric Haeger Establishes New Scholarship Program to Support Future Medical Professionals and Healthcare Innovation https://ml.globenewswire.com/media/46ed0337-1c54-4d9f-b03a-6578ae568fc8/medium/dr-eric-haeger-scholarship.png https://www.andorrahealthwatch.com/article/905735070-adcare-hospital-hosts-eagle-scout-led-initiative-to-support-patients-in-recovery Andorra Health Watch en PressRelease 2026-04-14T18:45:00+00:00 AdCare Hospital Hosts Eagle Scout-Led Initiative to Support Patients in Recovery https://ml.globenewswire.com/media/d233fb10-552e-4814-b746-a0797cce4b93/small/logo-adcare-png.png https://www.andorrahealthwatch.com/article/905735131-exit-156-capital-and-nightware-announce-strategic-investment-partnership Andorra Health Watch en PressRelease 2026-04-14T18:33:00+00:00 EXIT 156 CAPITAL AND NIGHTWARE ANNOUNCE STRATEGIC INVESTMENT PARTNERSHIP https://ml.globenewswire.com/media/a6f5b4f9-8819-48df-bbb5-58f7d222ab16/small/nightware-inc-logo.png https://www.andorrahealthwatch.com/article/905734763-microbot-medical-to-highlight-commercial-achievements-leading-to-the-full-market-release-fmr-of-the-liberty-endovascular-robotic-system-at-the Andorra Health Watch en PressRelease 2026-04-14T18:30:00+00:00 Microbot Medical® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/346df7fb-c134-40c2-970a-39bcbaf974cd/small/mbot-logo-rgb-jpg.jpg https://www.andorrahealthwatch.com/article/905735393-supporting-women-s-health-can-unlock-workforce-potential-here-s-what-employers-and-allies-can-do Andorra Health Watch en PressRelease 2026-04-14T18:24:12+00:00 Supporting Women’s Health Can Unlock Workforce Potential. Here’s What Employers and Allies Can Do https://ml.globenewswire.com/media/669af2b2-a5eb-433a-b6da-54ef95a7977b/small/whcc-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905735430-le-soutien-la-sant-des-femmes-maximise-le-potentiel-de-la-main-d-uvre-voici-comment-les-employeurs-et-les-alli-s-peuvent-aider Andorra Health Watch en PressRelease 2026-04-14T18:24:12+00:00 Le soutien à la santé des femmes maximise le potentiel de la main-d’œuvre. Voici comment les employeurs et les alliés peuvent aider https://ml.globenewswire.com/media/669af2b2-a5eb-433a-b6da-54ef95a7977b/small/whcc-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905735110-scripps-encinitas-named-among-top-100-hospitals-in-the-u-s Andorra Health Watch en PressRelease 2026-04-14T18:17:15+00:00 Scripps Encinitas Named Among Top 100 Hospitals in the U.S. https://ml.globenewswire.com/media/Y2Q0NWE4NGUtZjcyNi00NDM4LWJjMDQtNGRiYWE5MGJkODI4LTExMDA0OTEtMjAyNi0wNC0xNC1lbg==/tiny/Scripps-Health.png https://www.andorrahealthwatch.com/article/905735261-galera-therapeutics-and-obsidian-therapeutics-announce-merger-agreement-and-350-million-concurrent-private-placement Andorra Health Watch en PressRelease 2026-04-14T18:08:10+00:00 Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement https://ml.globenewswire.com/media/d4232a7c-0097-427f-af68-18288ab26fa6/small/galera-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905721688-excellent-brain-ltd-launches-new-android-version-for-neurofeedback-for-adhd-platform Andorra Health Watch en PressRelease 2026-04-14T17:29:00+00:00 Excellent Brain Ltd. Launches New Android Version for Neurofeedback for ADHD Platform https://pressranger.s3.us-west-1.amazonaws.com/3230185/WhatsApp-Image-2026-04-05-at-12.59.39.jpeg https://www.andorrahealthwatch.com/article/905721597-van-nuys-premier-rehabilitation-center-injury-docs-celebrates-10-000th-patient Andorra Health Watch en PressRelease 2026-04-14T16:37:00+00:00 Van Nuys' Premier Rehabilitation Center, Injury Docs, Celebrates 10,000th Patient https://pressranger.s3.us-west-1.amazonaws.com/3228271/SCR-20260410-mizp.png https://www.andorrahealthwatch.com/article/905707675-ose-immunotherapeutics-evolves-its-leadership-team Andorra Health Watch en PressRelease 2026-04-14T16:00:00+00:00 OSE Immunotherapeutics Evolves its Leadership Team https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ose-logo-horizontal-rvb-png.png https://www.andorrahealthwatch.com/article/905707763-ose-immunotherapeutics-fait-voluer-son-quipe-de-direction Andorra Health Watch en PressRelease 2026-04-14T16:00:00+00:00 OSE Immunotherapeutics fait évoluer son équipe de direction https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ https://www.andorrahealthwatch.com/article/905708063-comprehensive-healthcare-launches-just-in-time-prescriber-scheduling-to-improve-access-to-behavioral-health-medication-services Andorra Health Watch en PressRelease 2026-04-14T16:00:00+00:00 Comprehensive Healthcare Launches “Just In Time” Prescriber Scheduling to Improve Access to Behavioral Health Medication Services https://ml.globenewswire.com/media/87b3c91d-8292-48c4-aaff-e3ee4e518ee3/small/ch-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905708364-providence-saint-john-s-health-center-announces-largest-philanthropic-gift-in-its-history-through-transformative-stan-lucas-legacy Andorra Health Watch en PressRelease 2026-04-14T16:00:00+00:00 Providence Saint John’s Health Center Announces Largest Philanthropic Gift in Its History Through Transformative Stan Lucas Legacy https://ml.globenewswire.com/media/5cec38c7-016b-458b-b0cf-462a36e4f605/small/saintjohnshealthcenter-2l-clr-4cp-lowerres-jpg.jpg https://www.andorrahealthwatch.com/article/905708957-ascellahealth-inaugurates-strategic-advisory-council-with-founding-members-advances-pharmacy-benefits-ecosystem-through-technology-deployment-and Andorra Health Watch en PressRelease 2026-04-14T15:30:00+00:00 AscellaHealth Inaugurates Strategic Advisory Council, With Founding Members, Advances Pharmacy Benefits Ecosystem Through Technology Deployment and Specialty Expertise https://ml.globenewswire.com/media/5278c55f-330c-41a1-8446-d8b1a07bbc55/small/ah-logo-colornotag-4x-png.png https://www.andorrahealthwatch.com/article/905699380-vietnam-shocks-the-world-with-animal-to-human-organ-transplantation-technology Andorra Health Watch en PressRelease 2026-04-14T14:56:25+00:00 Vietnam Shocks the World With Animal-To-Human Organ Transplantation Technology https://ml.globenewswire.com/media/8986a8b7-9a74-40ca-bd2f-eef76084e773/medium/vgct-s-source.jpg https://www.andorrahealthwatch.com/article/905695842-major-shareholder-announcement Andorra Health Watch en PressRelease 2026-04-14T14:44:22+00:00 Major Shareholder Announcement https://ml-eu.globenewswire.com/media/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce/small/logo-jpg.jpg https://www.andorrahealthwatch.com/article/905697702-advanced-radiation-centers-of-new-york-launches-softray-therapy-offering-new-non-surgical-relief-of-inflammatory-tendon-and-arthritis-pain Andorra Health Watch en PressRelease 2026-04-14T14:04:00+00:00 Advanced Radiation Centers of New York Launches SoftRay™ Therapy, Offering New Non-Surgical Relief of Inflammatory, Tendon and Arthritis Pain https://ml.globenewswire.com/media/de310bc0-7bc1-48f5-b455-ca8f8ffd0472/medium/softray-therapy-logo.png https://www.andorrahealthwatch.com/article/905695461-zealand-pharma-appoints-eric-rojas-as-vice-president-and-head-of-investor-relations Andorra Health Watch en PressRelease 2026-04-14T14:00:00+00:00 Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations https://ml-eu.globenewswire.com/media/b505bacc-6953-4eb4-ab25-e03008f97b92/medium/eric-rojas.jpg https://www.andorrahealthwatch.com/article/905696037-award-winning-medical-alert-system-bay-alarm-medical-launches-caregiver-sos-youtube-series-to-support-family-caregivers Andorra Health Watch en PressRelease 2026-04-14T14:00:00+00:00 Award-winning Medical Alert System Bay Alarm Medical Launches 'Caregiver SOS' YouTube Series to Support Family Caregivers https://pressranger.s3.us-west-1.amazonaws.com/3140430/Screenshot-2026-03-06-at-12.32.15%E2%80%AFPM.png https://www.andorrahealthwatch.com/article/905696490-neion-bio-strengthens-genome-engineering-leadership-with-appointment-of-colossal-biosciences-veteran-james-kehler Andorra Health Watch en PressRelease 2026-04-14T14:00:00+00:00 Neion Bio Strengthens Genome Engineering Leadership with Appointment of Colossal Biosciences Veteran James Kehler https://ml.globenewswire.com/media/e37518bc-d9ef-45ce-99a7-35e82f143444/medium/dr-james-kehler.jpg https://www.andorrahealthwatch.com/article/905696688-reducing-administrative-burden-raises-medicaid-provider-satisfaction-by-50-new-study-finds Andorra Health Watch en PressRelease 2026-04-14T14:00:00+00:00 Reducing Administrative Burden Raises Medicaid Provider Satisfaction by 50%, New Study Finds https://ml.globenewswire.com/media/24cdff2f-7c95-4f21-aebb-25c4628d94e7/small/gainwell-logo-suite-061720-logosuite-png-gainwell-logo-150-r.png https://www.andorrahealthwatch.com/article/905697695-hibercell-to-present-preclinical-data-demonstrating-the-enhanced-antitumor-activity-of-hc-7366-in-combination-with-vegfr-tkis-in-clear-cell-renal-cell Andorra Health Watch en PressRelease 2026-04-14T14:00:00+00:00 HiberCell to Present Preclinical Data Demonstrating the Enhanced Antitumor Activity of HC-7366 in Combination with VEGFR-TKIs in Clear Cell Renal Cell Carcinoma (ccRCC) https://ml.globenewswire.com/media/d168805a-8691-40f2-abcf-fb63a607f112/small/hybercell-jpg.jpg https://www.andorrahealthwatch.com/article/905697837-grand-river-aseptic-manufacturing-announces-100-million-investment-in-sterile-manufacturing-capabilities Andorra Health Watch en PressRelease 2026-04-14T13:55:44+00:00 Grand River Aseptic Manufacturing Announces $100 Million Investment in Sterile Manufacturing Capabilities https://ml.globenewswire.com/media/OTBkMmRlZDktNGMxYi00Mjk1LWE0YWMtZTBhYjhlOTMyMTFhLTUwMDE1MTE4Ny0yMDI2LTA0LTE0LWVu/tiny/Grand-River-Aseptic-Manufactur.png https://www.andorrahealthwatch.com/article/905697955-penn-highlands-healthcare-addresses-community-needs Andorra Health Watch en PressRelease 2026-04-14T13:44:34+00:00 Penn Highlands Healthcare Addresses Community Needs https://ml.globenewswire.com/media/ZGEyZjE1ZWMtZDA4MC00MmM1LWI0ZmQtNmVlMTM5ODUxMDgzLTEyNTYxMzgtMjAyNi0wNC0xNC1lbg==/tiny/Penn-Highlands-Healthcare.png https://www.andorrahealthwatch.com/article/905686836-culture-biosciences-announces-strategic-addition-to-its-board-of-directors-to-accelerate-hardware-commercialization-and-saas-growth Andorra Health Watch en PressRelease 2026-04-14T13:30:00+00:00 Culture Biosciences Announces Strategic Addition to Its Board of Directors to Accelerate Hardware Commercialization and SaaS Growth https://ml.globenewswire.com/media/ce8c1148-eecd-40b0-b1b7-f858ab8c3c4f/small/culture-logo-one-color-rgb-1500px-300ppi-1-1-png.png https://www.andorrahealthwatch.com/article/905685691-virtuix-delivers-omni-one-to-florida-gulf-coast-university-for-use-in-physical-therapy-and-clinical-simulation Andorra Health Watch en PressRelease 2026-04-14T13:15:00+00:00 Virtuix Delivers Omni One to Florida Gulf Coast University for Use in Physical Therapy and Clinical Simulation https://ml.globenewswire.com/media/2ba7d28b-48bc-45db-b49e-929295456dc1/medium/omni-one-at-fgu-s-marieb-college-of-health-and-human-service.jpeg https://www.andorrahealthwatch.com/article/905685932-myriad-genetics-expands-access-for-mychoice-test-to-prostate-cancer-patients-in-japan Andorra Health Watch en PressRelease 2026-04-14T13:15:00+00:00 Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan https://ml.globenewswire.com/media/5cb679cf-5a10-4b95-8cf7-fd1d0b56721a/small/myriad-s-stacked-png.png https://www.andorrahealthwatch.com/article/905685481-nextech-reduces-healthcare-s-payment-reconciliation-burden-with-reimagined-embedded-payment-processing-platform Andorra Health Watch en PressRelease 2026-04-14T13:00:00+00:00 Nextech Reduces Healthcare’s Payment Reconciliation Burden with Reimagined Embedded Payment Processing Platform https://ml.globenewswire.com/media/2b32c79b-9e9d-48d1-ae49-77d47537ae62/small/nextech-logo-jpg-jpg.jpg https://www.andorrahealthwatch.com/article/905685781-alliance-direct-benefits-launches-alliance-complete-as-demand-grows-for-simplified-bundled-support-offerings Andorra Health Watch en PressRelease 2026-04-14T13:00:00+00:00 Alliance Direct Benefits Launches Alliance Complete as Demand Grows for Simplified, Bundled Support Offerings https://ml.globenewswire.com/media/ZGM1MDA4YTEtODYzZi00YzgzLThkODAtMjEwNWJhZjU2NjQ2LTUwMDE2MDEwNC0yMDI2LTA0LTE0LWVu/tiny/Alliance-Direct-Benefits.png https://www.andorrahealthwatch.com/article/905686904-healthedge-partners-with-ellipsis-health-to-scale-care-management-through-ai-powered-virtual-nursing Andorra Health Watch en PressRelease 2026-04-14T13:00:00+00:00 HealthEdge® Partners with Ellipsis Health to Scale Care Management Through AI-Powered Virtual Nursing https://ml.globenewswire.com/media/18d2dfaf-8f95-4f15-99e6-ae8282b42123/small/healthedge-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905686993-neomorph-to-highlight-progress-in-targeted-protein-degradation-science-at-the-american-association-for-cancer-research-annual-meeting Andorra Health Watch en PressRelease 2026-04-14T13:00:00+00:00 Neomorph to Highlight Progress in Targeted Protein Degradation Science at the American Association for Cancer Research Annual Meeting https://ml.globenewswire.com/media/d00180c1-5def-41b6-95c7-018ca5e07565/small/neomorph-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905687330-haystack-health-appoints-digital-health-leader-bill-snyder-as-chief-executive-officer Andorra Health Watch en PressRelease 2026-04-14T13:00:00+00:00 Haystack Health Appoints Digital Health Leader Bill Snyder as Chief Executive Officer https://ml.globenewswire.com/media/f6629b37-d06b-4203-a6cd-f233134c4f32/small/hh-logo-png.png https://www.andorrahealthwatch.com/article/905687785-merakris-therapeutics-and-ifyber-collaboration-receives-top-sawc-research-award-for-mtx-001-wound-healing-study-in-human-skin-model Andorra Health Watch en PressRelease 2026-04-14T13:00:00+00:00 Merakris Therapeutics and iFyber Collaboration Receives Top SAWC Research Award for MTX-001 Wound Healing Study in Human Skin Model https://ml.globenewswire.com/media/5b9c5fed-3332-4d4d-b8b6-6ab1b15faaed/small/mrks-brand-logo-final-fullcolor-png.png https://www.andorrahealthwatch.com/article/905685907-just-salad-opens-in-east-amherst-n-y Andorra Health Watch en PressRelease 2026-04-14T12:57:00+00:00 Just Salad Opens in East Amherst, N.Y. https://ml.globenewswire.com/media/0bfa206d-0a40-4b13-a05a-267ebef25a6a/medium/just-salad-east-amherst-new-york-storefront.jpg https://www.andorrahealthwatch.com/article/905688308-entera-bio-to-host-key-opinion-leader-webinar-highlighting-the-osteoporosis-treatment-landscape-and-the-opportunity-for-eb613 Andorra Health Watch en PressRelease 2026-04-14T12:45:00+00:00 Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613 https://ml.globenewswire.com/media/9b4ae2bf-733d-4180-b48c-d0fa3f26c81a/small/logo-png.png https://www.andorrahealthwatch.com/article/905688406-actuate-therapeutics-announces-nature-medicine-publication-of-clinical-trial-results-showing-doubling-of-the-rate-of-survival-with-elraglusib-plus Andorra Health Watch en PressRelease 2026-04-14T12:45:00+00:00 Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma https://ml.globenewswire.com/media/f65ca94c-eff8-4376-ac67-ded1b03b3bcc/small/actuatetx-logo-color300-jpg.jpg https://www.andorrahealthwatch.com/article/905688494-extendicare-announces-closing-of-450-million-inaugural-offering-of-investment-grade-senior-unsecured-notes Andorra Health Watch en PressRelease 2026-04-14T12:39:06+00:00 Extendicare Announces Closing of $450 Million Inaugural Offering of Investment Grade Senior Unsecured Notes https://ml.globenewswire.com/media/6d631964-eede-4e2c-912c-58ab7d1dc35f/small/extendicare-jpg.jpg https://www.andorrahealthwatch.com/article/905686858-cellectar-enrolls-first-patient-in-clr-125-auger-emitting-radioconjugate-phase-1b-clinical-trial-targeting-refractory-triple-negative-breast-cancer Andorra Health Watch en PressRelease 2026-04-14T12:35:00+00:00 Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) https://ml.globenewswire.com/media/980abc5d-826f-4ac3-ad81-f07d69b34af6/small/cellectar-logo-1-jpg.jpg https://www.andorrahealthwatch.com/article/905686003-pelthos-therapeutics-to-participate-in-piper-sandler-spring-biopharma-symposium Andorra Health Watch en PressRelease 2026-04-14T12:30:00+00:00 Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium https://ml.globenewswire.com/media/7d71f2d0-a48f-4fe0-a49c-138de21bc0e1/small/pelthos-logo-rgb-png.png https://www.andorrahealthwatch.com/article/905686896-cytodyn-to-present-at-the-aacr-annual-meeting-2026 Andorra Health Watch en PressRelease 2026-04-14T12:30:00+00:00 CytoDyn to Present at the AACR Annual Meeting 2026 https://ml.globenewswire.com/media/3b426b4d-6299-4c23-9f95-058174a5b7be/small/new-logo-png.png https://www.andorrahealthwatch.com/article/905687404-clinical-data-supporting-targeted-chemotherapeutic-delivery-via-renovorx-s-tamp-therapy-platform-presented-at-2026-sir-annual-scientific-meeting Andorra Health Watch en PressRelease 2026-04-14T12:30:00+00:00 Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting https://ml.globenewswire.com/media/e18bf823-ff44-4bbd-82b9-3a311d58dad8/small/final-logo-horizontal-png.png https://www.andorrahealthwatch.com/article/905688178-join-nexalin-s-exclusive-live-investor-webinar-and-q-a-session-on-april-21 Andorra Health Watch en PressRelease 2026-04-14T12:30:00+00:00 Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21 https://ml.globenewswire.com/media/7f481b55-16b6-4c8a-8356-30d54079a605/small/nexalin-jpg.jpg https://www.andorrahealthwatch.com/article/905688250-meiragtx-to-present-3-year-data-from-the-phase-1-aquax-clinical-study-of-aav-haqp1-for-the-treatment-of-grade-2-3-radiation-induced-xerostomia-on Andorra Health Watch en PressRelease 2026-04-14T12:30:00+00:00 MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026 https://ml.globenewswire.com/media/6b45b8d0-975e-494b-8a46-b88360aa1791/small/mgx-logo-png.png https://www.andorrahealthwatch.com/article/905688290-tomi-reports-strong-q1-2026-sales-of-high-margin-bit-solution-indicating-positive-growth-trends Andorra Health Watch en PressRelease 2026-04-14T12:30:00+00:00 TOMI Reports Strong Q1 2026 Sales of High-Margin BIT Solution, Indicating Positive Growth Trends https://ml.globenewswire.com/media/f8c7c513-0121-4507-84b7-3680626d9cf3/small/tomi-jpg.jpg https://www.andorrahealthwatch.com/article/905687539-biomerica-launches-infoods-ibs-in-canada-through-partnerships-with-phoenix-airmid-biomedical-and-canalt-health-labs Andorra Health Watch en PressRelease 2026-04-14T12:19:00+00:00 Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs https://ml.globenewswire.com/media/3461b9f0-3e95-484f-96e9-71608fc20239/small/biomerica-png.png https://www.andorrahealthwatch.com/article/905673841-inspira-technologies-appoints-yoav-rozanovich-as-chief-business-officer-to-drive-immediate-revenue-growth-and-quantum-expansion Andorra Health Watch en PressRelease 2026-04-14T12:01:00+00:00 Inspira Technologies Appoints Yoav Rozanovich as Chief Business Officer to Drive Immediate Revenue Growth and Quantum Expansion https://ml.globenewswire.com/media/6a4eabfe-c9ec-40d1-87fc-6f0d8e6e408c/small/screenshot-2025-04-02-at-19-21-06-png.png https://www.andorrahealthwatch.com/article/905669423-community-routes-access-to-mental-health-care-provides-continued-funding-for-mental-health-services-at-free-charitable-clinics Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics https://ml-eu.globenewswire.com/media/c2001734-949b-4cc2-8021-b4b64eda1f13/small/teva-rgb-jpeg-jpg.jpg https://www.andorrahealthwatch.com/article/905669681-amneal-launches-first-two-respiratory-metered-dose-inhalation-products-in-the-u-s Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S. https://ml.globenewswire.com/media/a20d6f40-90af-422f-ab14-47208fdbad2f/small/amneal-rgb-k-png.png https://www.andorrahealthwatch.com/article/905669769-biovie-announces-abstract-accepted-for-presentation-at-the-2026-american-academy-of-neurology-annual-meeting Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting https://ml.globenewswire.com/media/f437d04b-c089-46eb-bca8-7ef64f68bc9b/small/biovie-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905669779-grace-therapeutics-announces-abstract-highlighting-strive-on-phase-3-trial-results-accepted-for-presentation-at-aan-2026 Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026 https://ml.globenewswire.com/media/c71c0a95-caed-4520-87a9-ac7fefef3f07/small/grce-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905670492-er-kim-signs-exclusive-distribution-agreement-with-leo-pharma-a-s-to-commercialize-loqtorzi-toripalimab-for-nasopharyngeal-and-oesophageal-cancers Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 Er-Kim Signs Exclusive Distribution Agreement with LEO Pharma A/S to Commercialize LOQTORZI® (toripalimab) for Nasopharyngeal and Oesophageal Cancers https://ml.globenewswire.com/media/37d25207-4dc0-4c58-b0cc-d589d363d644/small/erkim-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905670506-hinge-bio-announces-first-subject-dosed-in-phase-1-trial-of-hb2198-a-novel-b-cell-depleting-agent-for-treating-autoimmune-disease Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 Hinge Bio Announces First Subject Dosed in Phase 1 Trial of HB2198, a Novel B cell Depleting Agent, for Treating Autoimmune Disease https://ml.globenewswire.com/media/62e1a1c6-154c-4dec-bfb4-79d43b015626/small/hinge-logo-color-2021-jpg.jpg https://www.andorrahealthwatch.com/article/905671256-genecentric-to-present-data-on-fragmentomics-based-expressct-liquid-biopsy-technology-at-aacr-2026 Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 GeneCentric to Present Data on Fragmentomics-Based ExpressCT™ Liquid Biopsy Technology at AACR 2026 https://ml.globenewswire.com/media/90d634f2-8dea-4f53-805f-e1e0eaa71133/small/genecentric-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905671300-rivus-pharmaceuticals-announces-first-patients-dosed-in-amplify-phase-2-trial-for-hu6-in-mash Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 Rivus Pharmaceuticals Announces First Patients Dosed in AMPLIFY Phase 2 Trial for HU6 in MASH https://ml.globenewswire.com/media/b85bbdee-9fda-4cf2-a14f-d2d608f0b949/small/rivus-pharmaceuticals-logo-png.png https://www.andorrahealthwatch.com/article/905671534-carlsmed-inc-to-report-first-quarter-2026-financial-results-on-may-5-2026 Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026 https://ml.globenewswire.com/media/ee16eff2-e0d6-40ca-95c5-4dd84bb4cc5f/small/carlsmed-png.png https://www.andorrahealthwatch.com/article/905671584-nanox-announces-collaboration-with-meir-medical-center-to-deploy-nanox-arc-for-orthopedic-imaging-clinical-study Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 Nanox Announces Collaboration with Meir Medical Center to Deploy Nanox.ARC for Orthopedic Imaging Clinical Study https://ml.globenewswire.com/media/57c1ffd6-84b3-46b9-b9b3-76666e6ba5a2/small/nano-logo-002-jpg.jpg https://www.andorrahealthwatch.com/article/905672627-corbus-pharmaceuticals-announces-last-patient-first-visit-in-canyon-1-study-of-crb-913-for-the-treatment-for-obesity Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity https://ml.globenewswire.com/media/459d6fb1-b336-4d47-8aa1-f9198bda891d/small/corbus-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905672678-tempest-appoints-andrew-fang-ph-d-as-head-of-business-development-to-advance-strategic-partnerships-and-global-licensing-efforts Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts https://ml.globenewswire.com/media/6ddb04fb-e5ac-416b-b90b-b4cbf51dc538/small/blue-logo-stacked-jpg.jpg https://www.andorrahealthwatch.com/article/905672686-genvor-announces-strategic-memorandum-of-understanding-with-canlab-international-to-advance-commercial-peptide-pipeline Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 Genvor Announces Strategic Memorandum of Understanding with Canlab International™ to Advance Commercial Peptide Pipeline https://ml.globenewswire.com/media/8533fef9-aa8f-43c5-9088-39ab06147641/small/43464-png.png https://www.andorrahealthwatch.com/article/905672832-real-world-evidence-and-industry-momentum-builds-for-imdx-s-flagship-graftassure-assay Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay https://ml.globenewswire.com/media/418fe8d1-a6a4-4025-84ba-56f14ee83865/small/imdx-logo-png.png https://www.andorrahealthwatch.com/article/905673675-calidi-biotherapeutics-announces-speaker-presentation-at-iovc-conference-in-reykjav-k-iceland-on-april-28th-highlighting-the-redtail-platform-s Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy https://ml.globenewswire.com/media/9e574b79-be62-4805-a4b4-cb0b7dcc5fbd/small/calidibiotherapeutics-logo-2x-jpg.jpg https://www.andorrahealthwatch.com/article/905674131-aclarion-receives-pinnacle-award-for-ai-innovation Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 Aclarion Receives Pinnacle Award for AI Innovation https://ml.globenewswire.com/media/6650177f-80b7-4c94-afb4-fc63aa3ada98/small/logo-png.png https://www.andorrahealthwatch.com/article/905674226-r1-announces-revenue-performance-solutions-powered-by-phare-os-to-help-providers-navigate-growing-complexity-and-margin-pressure Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 R1 Announces Revenue Performance Solutions Powered by Phare OS to Help Providers Navigate Growing Complexity and Margin Pressure https://ml.globenewswire.com/media/728189a4-e254-443f-8452-315403fd70f4/small/r1-logo-black-25-947x676-jpg.jpg https://www.andorrahealthwatch.com/article/905674385-prenetics-im8-health-partners-with-vitamin-angels-to-combat-global-malnutrition-commits-to-impacting-400-000-mothers-and-children-in-year-one Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 Prenetics’ IM8 Health Partners with Vitamin Angels to Combat Global Malnutrition, Commits to Impacting 400,000 Mothers and Children in Year One https://ml.globenewswire.com/media/106dbe1a-a6e1-49d9-97a2-c5609258bdc7/small/pre-logo-2026-png.png https://www.andorrahealthwatch.com/article/905674450-clairity-announces-update-to-nccn-guidelines-to-include-ai-mammogram-based-risk-tool-to-identify-future-breast-cancer-risk-in-women-missed-by Andorra Health Watch en PressRelease 2026-04-14T12:00:00+00:00 Clairity Announces Update to NCCN Guidelines to Include AI Mammogram-Based Risk Tool to Identify Future Breast Cancer Risk in Women Missed by Traditional Methods https://ml.globenewswire.com/media/0087b812-cef6-4183-8b7c-093385f3bcb5/small/clairitylogo-fullcolor-vertical-rgb-png.png https://www.andorrahealthwatch.com/article/905671949-avita-medical-announces-positive-interim-results-from-cohealyx-study-demonstrating-accelerated-time-to-skin-grafting Andorra Health Watch en PressRelease 2026-04-14T11:45:00+00:00 AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting https://ml.globenewswire.com/media/53ad8139-952a-4470-9ede-2f3bf0521f16/small/avita-png.png https://www.andorrahealthwatch.com/article/905674267-clearmind-medicine-s-cmnd-100-meets-primary-endpoint-in-fda-approved-phase-i-iia-clinical-trial-for-alcohol-use-disorder Andorra Health Watch en PressRelease 2026-04-14T11:32:00+00:00 Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder https://ml.globenewswire.com/media/bd17cbf4-8124-4f86-8a4c-1fafbb6785af/small/logo-jpg.jpg https://www.andorrahealthwatch.com/article/905670306-sanara-medtech-inc-to-report-first-quarter-2026-financial-results-on-may-12-2026 Andorra Health Watch en PressRelease 2026-04-14T11:30:00+00:00 Sanara MedTech Inc. to Report First Quarter 2026 Financial Results on May 12, 2026 https://ml.globenewswire.com/media/591eb30b-d3e4-428c-9cd6-536215925b01/small/logo-jpg.jpg https://www.andorrahealthwatch.com/article/905671016-profound-medical-to-participate-in-the-2026-bloom-burton-co-healthcare-investor-conference Andorra Health Watch en PressRelease 2026-04-14T11:30:00+00:00 Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference https://ml.globenewswire.com/media/94d9e057-9de3-430c-9a19-b41ff3e06a1e/small/profound-logo-cmyk-copy-jpg.jpg https://www.andorrahealthwatch.com/article/905671585-praxis-precision-medicines-announces-fda-acceptance-of-new-drug-application-for-ulixacaltamide-hcl-in-patients-with-essential-tremor Andorra Health Watch en PressRelease 2026-04-14T11:30:00+00:00 Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor https://ml.globenewswire.com/media/bff1e728-30ed-46c6-81e1-8bbc795929c0/small/01-primarylogo-color-bluex-100-jpg.jpg https://www.andorrahealthwatch.com/article/905672048-anavex-life-sciences-highlights-new-scientific-findings-on-shared-biology-between-autism-and-alzheimer-s-disease Andorra Health Watch en PressRelease 2026-04-14T11:30:00+00:00 Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease https://ml.globenewswire.com/media/1b0f858f-4f7f-4f50-b691-a25307283fb5/small/anavexlogor-transparent-3x-png.png https://www.andorrahealthwatch.com/article/905674084-medicenna-to-present-at-the-2026-bloom-burton-co-healthcare-investor-conference Andorra Health Watch en PressRelease 2026-04-14T11:30:00+00:00 Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference https://ml.globenewswire.com/media/1644a38b-bed9-4a76-96fa-d57dd028e650/small/medicenna-jpg.jpg https://www.andorrahealthwatch.com/article/905674299-avacta-ceo-christina-coughlin-named-as-one-of-in-vivo-s-2026-rising-leaders Andorra Health Watch en PressRelease 2026-04-14T11:26:11+00:00 Avacta CEO Christina Coughlin Named as One of In Vivo's 2026 Rising Leaders https://ml.globenewswire.com/media/63584766-21c6-42e8-944c-7103432b045b/small/avacta-logo-full-color-rgb-oct-2024-jpg.jpg https://www.andorrahealthwatch.com/article/905669756-adagene-adds-industry-veteran-peter-lebowitz-to-scientific-and-strategic-advisory-board Andorra Health Watch en PressRelease 2026-04-14T11:00:00+00:00 Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board https://ml.globenewswire.com/media/c377318b-edf7-42c0-8e7c-63a02bbe47b0/small/adagene-logo-gnw-png.png https://www.andorrahealthwatch.com/article/905669823-trained-therapeutix-discovery-s-chief-scientific-officer-dr-mulder-honored-with-fellowship-at-the-american-institute-for-medical-and-biological Andorra Health Watch en PressRelease 2026-04-14T11:00:00+00:00 Trained Therapeutix Discovery’s Chief Scientific Officer, Dr. Mulder, Honored with Fellowship at the American Institute for Medical and Biological Engineering (AIMBE) https://ml.globenewswire.com/media/5f6e0329-ec9c-4ab1-9659-d99b938cce16/small/trained-therapeutix-logo-png.png https://www.andorrahealthwatch.com/article/905671051-shopify-to-announce-first-quarter-2026-financial-results-may-5-2026 Andorra Health Watch en PressRelease 2026-04-14T11:00:00+00:00 Shopify to Announce First-Quarter 2026 Financial Results May 5, 2026 https://ml.globenewswire.com/media/28cdf29b-fa48-43e3-a710-ea3ab811a26c/small/shopify-logo-black-png.png https://www.andorrahealthwatch.com/article/905671069-axogen-inc-to-report-first-quarter-2026-financial-results-on-april-28-2026 Andorra Health Watch en PressRelease 2026-04-14T11:00:00+00:00 Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026 https://ml.globenewswire.com/media/3e4ffe78-2e9a-4972-915e-28c8477c84c1/small/axogen-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905671091-vitalhub-announces-novari-health-referral-central-intake-implementation-in-ontario Andorra Health Watch en PressRelease 2026-04-14T11:00:00+00:00 VitalHub Announces Novari Health Referral Central Intake Implementation in Ontario https://ml.globenewswire.com/media/fae8da93-7d5e-4eb4-9121-d724c8555bce/small/greylogo-png.png https://www.andorrahealthwatch.com/article/905672083-evolveimmune-therapeutics-to-present-update-on-lead-asset-evolve104-and-new-data-for-evolve-t-cell-engager-platform-at-2026-aacr-annual-meeting Andorra Health Watch en PressRelease 2026-04-14T11:00:00+00:00 EvolveImmune Therapeutics to Present Update on Lead Asset EVOLVE104 and New Data for EVOLVE T Cell Engager Platform at 2026 AACR Annual Meeting https://ml.globenewswire.com/media/43892ec0-88ad-4f85-b32e-7d049f9ed422/small/evolveimmune-png.png https://www.andorrahealthwatch.com/article/905673210-ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Andorra Health Watch en PressRelease 2026-04-14T11:00:00+00:00 Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905673892-ligand-partner-travere-therapeutics-receives-full-fda-approval-for-filspari-sparsentan-in-fsgs Andorra Health Watch en PressRelease 2026-04-14T11:00:00+00:00 Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS https://ml.globenewswire.com/media/1fe91aa2-494e-4b30-89e8-cad771bbaabf/small/new-ligand-logo-png.png https://www.andorrahealthwatch.com/article/905674161-tiziana-life-sciences-announces-late-breaking-poster-accepted-for-presentation-at-the-7th-world-parkinson-congress Andorra Health Watch en PressRelease 2026-04-14T11:00:00+00:00 Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress https://ml.globenewswire.com/media/991c340c-a083-4bcb-ad41-e7eea83f6f97/small/tiziana-logo-png.png https://www.andorrahealthwatch.com/article/905658105-genmab-announces-net-sales-of-darzalex-daratumumab-for-first-quarter-of-2026 Andorra Health Watch en PressRelease 2026-04-14T10:22:57+00:00 Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026 https://ml-eu.globenewswire.com/media/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce/small/logo-jpg.jpg https://www.andorrahealthwatch.com/article/905658895-ataibeckley-to-participate-in-upcoming-needham-healthcare-conferences Andorra Health Watch en PressRelease 2026-04-14T10:00:00+00:00 AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences https://ml.globenewswire.com/media/cea08bf4-0562-45ed-af5c-c9376c48a6eb/small/ataibeckley-horizontal-2color-png.png https://www.andorrahealthwatch.com/article/905659602-greenwich-lifesciences-provides-update-on-financing-strategy Andorra Health Watch en PressRelease 2026-04-14T10:00:00+00:00 Greenwich LifeSciences Provides Update on Financing Strategy https://ml.globenewswire.com/media/e0bfd967-b05f-43d2-91b4-d2a5d551df99/small/logo-edited-jpg.jpg https://www.andorrahealthwatch.com/article/905647186-nxera-pharma-s-quviviq-daridorexant-25mg-and-50mg-receives-approval-in-taiwan-for-the-treatment-of-insomnia Andorra Health Watch en PressRelease 2026-04-14T08:42:59+00:00 Nxera Pharma’s QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia https://ml-eu.globenewswire.com/media/5cc74d52-c86f-4e21-8684-3496281fee15/small/nxera-master-logo-rgb-black-1-png.png https://www.andorrahealthwatch.com/article/905636102-mestag-therapeutics-selected-to-present-targeted-ltbr-agonist-mst-0312-in-late-breaking-session-at-aacr-annual-meeting Andorra Health Watch en PressRelease 2026-04-14T07:30:00+00:00 Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting https://ml-eu.globenewswire.com/media/d47c1200-a3a8-42b0-b0b9-ffb74568b42c/small/mestag-tx-logo-png.png https://www.andorrahealthwatch.com/article/905636143-asgard-therapeutics-appoints-professor-dr-wolfram-brugger-as-chief-medical-officer-as-it-advances-transformative-personalized-off-the-shelf Andorra Health Watch en PressRelease 2026-04-14T07:30:00+00:00 Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development https://ml-eu.globenewswire.com/media/5afbd1fa-9d4b-48d2-8f4f-d262d5a69053/small/asgard-tx-rgb-png.png https://www.andorrahealthwatch.com/article/905614729-panntherapi-annonce-des-avanc-es-majeures-dans-son-d-veloppement-clinique-et-strat-gique Andorra Health Watch en PressRelease 2026-04-14T06:00:00+00:00 PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique https://ml-eu.globenewswire.com/media/79af9499-0fbe-4979-88f5-7c607773acb4/small/ https://www.andorrahealthwatch.com/article/905614774-renaissance-pharma-limited-an-essential-pharma-company-secures-fda-fast-track-designation-and-ind-clearance-for-daretabart-hu1418k322a-in Andorra Health Watch en PressRelease 2026-04-14T06:00:00+00:00 Renaissance Pharma Limited, an Essential Pharma company, secures FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A) in high-risk neuroblastoma https://ml-eu.globenewswire.com/media/31276511-f379-4a7a-90b6-af9fc9ac2aa0/small/66795319ca361c8d044a2cc6-essential-pharma-master-logo-png.png https://www.andorrahealthwatch.com/article/905614817-panntherapi-announces-significant-clinical-development-and-strategic-milestones Andorra Health Watch en PressRelease 2026-04-14T06:00:00+00:00 PannTheraPi Announces Significant Clinical Development and Strategic Milestones https://ml-eu.globenewswire.com/media/79af9499-0fbe-4979-88f5-7c607773acb4/small/logo-png.png https://www.andorrahealthwatch.com/article/905614845-kuros-biosciences-reports-51-year-over-year-increase-in-sales-in-the-first-three-months-of-2026 Andorra Health Watch en PressRelease 2026-04-14T05:00:00+00:00 Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 https://ml-eu.globenewswire.com/media/ad3777c9-af1f-4b09-a899-3b3d6b8e962d/small/kuros-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905593433-rapid-nutrition-strengthens-capital-markets-infrastructure-with-appointment-of-bowsprit-partners Andorra Health Watch en PressRelease 2026-04-14T03:00:00+00:00 Rapid Nutrition Strengthens Capital Markets Infrastructure with Appointment of Bowsprit Partners https://ml-eu.globenewswire.com/media/f5152816-94d7-4584-a49f-05ae66a44bf0/small/rapid-jpg.jpg https://www.andorrahealthwatch.com/article/905574910-elite-force-xl-male-enhancement-gummies-claims-evaluated-effective-men-s-formula-for-steel-power-support Andorra Health Watch en PressRelease 2026-04-14T01:36:27+00:00 Elite Force XL Male Enhancement Gummies Claims Evaluated: Effective Men's Formula for Steel Power Support https://zingfast.com/wp-content/uploads/2026/04/Elite-Force-XL-Male-Enhancement-Gummies.jpg https://www.andorrahealthwatch.com/article/905574767-vital-step-glp-1-claims-evaluated-trusted-doctor-prescribed-glp-1-weight-loss-medication-with-no-hidden-fees Andorra Health Watch en PressRelease 2026-04-14T01:11:21+00:00 Vital Step GLP-1 Claims Evaluated: Trusted Doctor-Prescribed GLP-1 Weight Loss Medication with No Hidden Fees https://zingfast.com/wp-content/uploads/2026/04/Vital-Step-GLP-1.jpg https://www.andorrahealthwatch.com/article/905565700-gloramd-face-lift-serum-claims-evaluated-liquid-anti-aging-wrinkle-serum-solution-for-skin-renewal Andorra Health Watch en PressRelease 2026-04-14T00:16:02+00:00 GloraMD Face Lift Serum Claims Evaluated: Liquid Anti-Aging Wrinkle Serum Solution for Skin Renewal https://zingfast.com/wp-content/uploads/2026/04/GloraMD-Face-Lift-Serum.jpg https://www.andorrahealthwatch.com/article/905557661-biomerica-reports-third-quarter-fiscal-2026-financial-results Andorra Health Watch en PressRelease 2026-04-13T22:57:27+00:00 Biomerica Reports Third Quarter Fiscal 2026 Financial Results https://ml.globenewswire.com/media/3461b9f0-3e95-484f-96e9-71608fc20239/small/biomerica-png.png https://www.andorrahealthwatch.com/article/905557520-clean-eye-claims-evaluated-the-cleaneye-vision-care-capsules-for-retina-clear-visual-support Andorra Health Watch en PressRelease 2026-04-13T22:46:54+00:00 Clean Eye Claims Evaluated: The CleanEye Vision Care Capsules for Retina Clear Visual Support https://zingfast.com/wp-content/uploads/2026/04/Clean-Eye.jpg https://www.andorrahealthwatch.com/article/905549775-ballad-health-s-program-for-assisting-uninsured-patients-earns-national-award-for-its-community-based-approach-to-serving-rural-appalachia Andorra Health Watch en PressRelease 2026-04-13T22:06:57+00:00 Ballad Health’s program for assisting uninsured patients earns national award for its community-based approach to serving rural Appalachia https://ml.globenewswire.com/media/MWQ0YWI3MDEtY2Q2Mi00NDk0LTk5MDAtNTEwNTEyYzRjY2Y5LTExMzUxNTItMjAyNi0wNC0xMy1lbg==/tiny/Ballad-Health.png https://www.andorrahealthwatch.com/article/905549588-aim-immunotech-provides-routine-update-on-annual-filings Andorra Health Watch en PressRelease 2026-04-13T22:00:00+00:00 AIM ImmunoTech Provides Routine Update on Annual Filings https://ml.globenewswire.com/media/8e85b83b-047f-4f99-9c51-1aa232ffe9bb/small/aimlogo-jpg.jpg https://www.andorrahealthwatch.com/article/905542434-xortx-announces-closing-of-acquisition-of-vectus-kidney-anti-fibrotic-asset Andorra Health Watch en PressRelease 2026-04-13T21:00:00+00:00 XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset https://ml.globenewswire.com/media/9898c4f8-b373-438a-abfa-709c4372a061/small/xortx-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905542368-spyre-therapeutics-announces-proposed-public-offering-of-its-common-stock Andorra Health Watch en PressRelease 2026-04-13T20:46:48+00:00 Spyre Therapeutics Announces Proposed Public Offering of its Common Stock https://ml.globenewswire.com/media/bc26a912-b583-43c6-8423-55a4ba2bf4bd/small/spyre-logo-horizontal-full-color-rgb-583px-300ppi-jpg.jpg https://www.andorrahealthwatch.com/article/905535759-immucell-bolsters-its-innovation-strategy-with-appointments-of-dr-gilles-guillemette-and-dr-anthony-dimarco-to-the-board-and-moves-to-a-smaller Andorra Health Watch en PressRelease 2026-04-13T20:38:05+00:00 ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors https://ml.globenewswire.com/media/680330c2-368b-4abc-9429-878b0c9fb1a2/small/immucell-jpg.jpg https://www.andorrahealthwatch.com/article/905535401-bioage-labs-to-present-at-25th-annual-needham-virtual-healthcare-conference Andorra Health Watch en PressRelease 2026-04-13T20:30:00+00:00 BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/d6df9eb5-87f7-4e2e-b503-8a7d8651428e/small/bioage-dark-logo-white-bg-500x500-png.png https://www.andorrahealthwatch.com/article/905535572-cema-cel-pivotal-trial-interim-data-highlight-strength-of-cellectis-allogeneic-car-t-platform Andorra Health Watch en PressRelease 2026-04-13T20:30:00+00:00 Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png https://www.andorrahealthwatch.com/article/905535574-les-donn-es-interm-diaires-de-l-essai-pivot-testant-cema-cel-mettent-en-vidence-la-solidit-de-la-plateforme-car-t-allog-nique-de-cellectis Andorra Health Watch en PressRelease 2026-04-13T20:30:00+00:00 Les données intermédiaires de l'essai pivot testant cema-cel mettent en évidence la solidité de la plateforme CAR-T allogénique de Cellectis https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png https://www.andorrahealthwatch.com/article/905535321-sana-biotechnology-and-mayo-clinic-announce-strategic-collaboration-focused-on-improving-care-in-type-1-diabetes-and-accelerating-development-of-sc451 Andorra Health Watch en PressRelease 2026-04-13T20:05:00+00:00 Sana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451 https://ml.globenewswire.com/media/2e5b81be-ddf0-4a60-85f1-3f17c242e8c2/small/sana-biotechnology-jpg.jpg https://www.andorrahealthwatch.com/article/905535567-bridgebio-oncology-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Andorra Health Watch en PressRelease 2026-04-13T20:05:00+00:00 BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/f5f2b913-06aa-4e1d-9368-55ff15fb3bd6/small/bbot-fullcolor-rgb-png.png https://www.andorrahealthwatch.com/article/905535390-celldex-to-present-at-upcoming-investor-conference Andorra Health Watch en PressRelease 2026-04-13T20:01:00+00:00 Celldex to Present at Upcoming Investor Conference https://ml.globenewswire.com/media/7a6cc287-087f-4e97-878f-7c1ed1dc5949/small/celldex-logo-rgb-png.png https://www.andorrahealthwatch.com/article/905535566-revolution-medicines-inc-announces-proposed-offerings-of-common-stock-and-convertible-senior-notes Andorra Health Watch en PressRelease 2026-04-13T20:01:00+00:00 Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes https://ml.globenewswire.com/media/771b34d9-586d-435a-a976-ab0ab847571b/small/balanced-green-primary-logo-medium-1000px-png.png https://www.andorrahealthwatch.com/article/905535570-allogene-therapeutics-announces-proposed-public-offering-of-175-million-of-common-stock Andorra Health Watch en PressRelease 2026-04-13T20:01:00+00:00 Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock https://ml.globenewswire.com/media/87e8712c-0741-409f-9942-c91b31e7c5e1/small/allogene-png.png https://www.andorrahealthwatch.com/article/905522414-celebrating-national-medical-laboratory-week Andorra Health Watch en PressRelease 2026-04-13T19:00:00+00:00 Celebrating National Medical Laboratory Week https://ml.globenewswire.com/media/ZWNlYTAwM2UtZDAwNS00MDFjLWJiY2ItZDE4ZTM2YzQyMTM2LTEwOTc1MzMtMjAyNi0wNC0xMy1lbg==/tiny/LifeLabs.png https://www.andorrahealthwatch.com/article/905516650-seer-confirms-receipt-of-unsolicited-proposal-and-director-candidate-nominations-from-radoff-jec-group Andorra Health Watch en PressRelease 2026-04-13T17:55:00+00:00 Seer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC Group https://ml.globenewswire.com/media/a5aaadad-13a1-4dbd-8ba2-d57cbbc610fb/small/seer-brandmark-rgb-full-jpg.jpg https://www.andorrahealthwatch.com/article/905516710-vital-hemp-gummies-launch-hemp-gummies-australia-nz-or-canada-relieves-anxiety-effective-reduces-pain-relax-stress-with-vital-hemp-2026 Andorra Health Watch en PressRelease 2026-04-13T17:39:33+00:00 Vital Hemp Gummies | Launch" Hemp Gummies Australia, NZ Or Canada Relieves Anxiety Effective Reduces Pain Relax Stress With Vital Hemp 2026 https://ml-eu.globenewswire.com/Resource/Download/3dd4c2ca-9658-477e-9266-ac54964587d8/image1.png https://www.andorrahealthwatch.com/article/905511446-dermatology-devices-market-to-reach-25-6-billion-by-2030-driven-by-rising-skin-cancer-incidence-and-aesthetic-demand Andorra Health Watch en PressRelease 2026-04-13T17:21:11+00:00 Dermatology Devices Market to Reach $25.6 Billion by 2030, Driven by Rising Skin Cancer Incidence and Aesthetic Demand https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://www.andorrahealthwatch.com/article/905511391-ask4sam-nyc-medical-malpractice-attorneys-silberstein-miklos-p-c-expands-focus-on-representing-patients-across-manhattan-brooklyn-and-queens Andorra Health Watch en PressRelease 2026-04-13T17:05:00+00:00 ASK4SAM NYC Medical Malpractice Attorneys Silberstein & Miklos, P.C. Expands Focus on Representing Patients Across Manhattan, Brooklyn and Queens https://pressranger.s3.us-west-1.amazonaws.com/3228765/8.png https://www.andorrahealthwatch.com/article/905506130-centre-for-neuro-skills-named-to-newsweek-s-america-s-greatest-midsize-workplaces-in-health-care-2026 Andorra Health Watch en PressRelease 2026-04-13T16:17:00+00:00 Centre for Neuro Skills Named to Newsweek’s America’s Greatest Midsize Workplaces in Health Care 2026 https://ml.globenewswire.com/media/3157a281-770d-4ef2-ade7-353df4ceca6b/medium/image2.png https://www.andorrahealthwatch.com/article/905506215-sienna-for-seniors-foundation-1-million-gift-advances-healthy-aging-research-at-ontario-tech-university Andorra Health Watch en PressRelease 2026-04-13T16:13:38+00:00 Sienna for Seniors Foundation $1 Million Gift Advances Healthy Aging Research at Ontario Tech University https://ml.globenewswire.com/media/9765702b-cb47-4b36-8255-d86b22ef3df3/medium/ontario-tech-university-and-sienna-senior-living-celebrate-t.jpg https://www.andorrahealthwatch.com/article/905506159-radical-catheter-technologies-announces-u-s-fda-510-k-clearance-for-its-6f-neurovascular-catheter-broadening-access-across-a-wide-range-of Andorra Health Watch en PressRelease 2026-04-13T16:05:00+00:00 Radical™ Catheter Technologies Announces U.S. FDA 510(k) Clearance for its 6F Neurovascular Catheter -- Broadening Access Across a Wide Range of Applications https://ml.globenewswire.com/media/5177f2ec-c584-4237-9659-cc7c70377b47/small/radical-catheter-stacked-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905501361-american-kidney-fund-announces-2026-class-of-corporate-members-supporting-work-to-fight-kidney-disease Andorra Health Watch en PressRelease 2026-04-13T15:37:08+00:00 American Kidney Fund Announces 2026 Class of Corporate Members Supporting Work to Fight Kidney Disease https://ml.globenewswire.com/media/MDkzZjJmMDYtN2I0OC00MTYwLWFlNTItZTBlNDJlMDBmNDk0LTExMDkwNTItMjAyNi0wNC0xMy1lbg==/tiny/American-Kidney-Fund.png https://www.andorrahealthwatch.com/article/905483211-biomx-accelerates-defense-technology-buildout-with-dfsl-acquisition Andorra Health Watch en PressRelease 2026-04-13T13:20:00+00:00 BiomX Accelerates Defense Technology Buildout with DFSL Acquisition https://ml.globenewswire.com/media/OGZiY2U5N2EtNDEzNS00MjcyLWJiZjUtODViOTA2ZTkxZjdhLTEzMjE4NzEtMjAyNi0wNC0xMy1lbg==/tiny/BiomX.png https://www.andorrahealthwatch.com/article/905482689-polypid-to-present-new-phase-3-shield-ii-data-demonstrating-d-plex-sustained-local-release-at-escmid-global-2026 Andorra Health Watch en PressRelease 2026-04-13T13:15:00+00:00 PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026 https://ml.globenewswire.com/media/6016c990-606d-49e6-a7a8-4d88bace509a/medium/figure-1.png https://www.andorrahealthwatch.com/article/905483265-safespace-global-corporation-announces-operational-expansion-to-support-commercial-deployment-of-its-ai-safety-platform-and-growing-revenue-activities Andorra Health Watch en PressRelease 2026-04-13T13:15:00+00:00 SafeSpace Global Corporation Announces Operational Expansion to Support Commercial Deployment of its AI-safety platform and Growing Revenue Activities https://ml.globenewswire.com/media/e95639ca-a47d-4c90-a44e-cf8a03b6a6d2/small/logo-jpg.jpg https://www.andorrahealthwatch.com/article/905482794-switchback-medical-signs-lease-for-18-000-square-foot-facility-in-costa-rica-s-coyol-free-trade-zone Andorra Health Watch en PressRelease 2026-04-13T13:00:00+00:00 Switchback Medical Signs Lease for 18,000 Square Foot Facility in Costa Rica’s Coyol Free Trade Zone https://ml.globenewswire.com/media/de124664-5d20-4955-8016-3dc40767830c/small/switchback-png.png https://www.andorrahealthwatch.com/article/905482824-switchback-medical-firma-contrato-de-arrendamiento-para-una-instalaci-n-de-18-000-pies-cuadrados-en-la-zona-franca-coyol-de-costa-rica Andorra Health Watch en PressRelease 2026-04-13T13:00:00+00:00 Switchback Medical firma contrato de arrendamiento para una instalación de 18,000 pies cuadrados en la Zona Franca Coyol de Costa Rica https://ml.globenewswire.com/media/de124664-5d20-4955-8016-3dc40767830c/small/switchback-png.png https://www.andorrahealthwatch.com/article/905482882-neomorph-announces-closing-of-100-million-series-b-financing Andorra Health Watch en PressRelease 2026-04-13T13:00:00+00:00 Neomorph Announces Closing of $100 Million Series B Financing https://ml.globenewswire.com/media/d00180c1-5def-41b6-95c7-018ca5e07565/small/neomorph-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905482931-senti-biosciences-to-present-on-logic-gated-cell-therapies-in-educational-session-at-aacr-annual-meeting-2026 Andorra Health Watch en PressRelease 2026-04-13T13:00:00+00:00 Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 https://ml.globenewswire.com/media/19732ef2-d354-4281-9dc5-6000f190dd83/small/sentibiologo-jpg.jpg https://www.andorrahealthwatch.com/article/905478607-free-oral-cancer-screenings-in-honor-of-oral-head-and-neck-cancer-awareness-month Andorra Health Watch en PressRelease 2026-04-13T12:45:00+00:00 Free Oral Cancer Screenings in Honor of Oral, Head and Neck Cancer Awareness Month https://ml.globenewswire.com/media/9472c27c-8b6d-4c87-95fd-31f1f0140263/small/usosm-logo-png.png https://www.andorrahealthwatch.com/article/905478665-xealth-to-facilitate-critical-discussion-among-health-system-executives-on-how-to-maximize-digital-health-value-at-becker-s-annual-meeting Andorra Health Watch en PressRelease 2026-04-13T12:33:00+00:00 Xealth to Facilitate Critical Discussion Among Health System Executives on How to Maximize Digital Health Value at Becker’s Annual Meeting https://ml.globenewswire.com/media/33a9b40b-a04e-464b-b15f-f7180c2168ce/small/picture1-png.png https://www.andorrahealthwatch.com/article/905478602-optum-united-healthcare-united-behavioral-health-expands-neurostar-tms-coverage-to-include-psychiatric-mental-health-nurse-practitioners Andorra Health Watch en PressRelease 2026-04-13T12:32:00+00:00 Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners https://ml.globenewswire.com/media/12db9039-d4bf-41a0-8b4a-324398e392b4/small/neuronetics-logo-rgb-purple-png.png https://www.andorrahealthwatch.com/article/905478464-alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer Andorra Health Watch en PressRelease 2026-04-13T12:30:00+00:00 ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer https://ml.globenewswire.com/media/0a1b4459-3df3-4c9f-ba29-ace8d7ad1b9a/small/alx-01-stacked-white-png.png https://www.andorrahealthwatch.com/article/905478584-oragenics-doses-first-patient-in-phase-iia-clinical-trial-of-onp-002-for-mild-traumatic-brain-injury Andorra Health Watch en PressRelease 2026-04-13T12:30:00+00:00 Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury https://ml.globenewswire.com/media/8b2c9d06-f009-4a6e-a465-8a1fe9640993/small/logo-jpg.jpg https://www.andorrahealthwatch.com/article/905478638-microbot-medical-commences-full-market-release-fmr-of-the-liberty-endovascular-robotic-system-in-the-u-s-at-the-society-of-interventional Andorra Health Watch en PressRelease 2026-04-13T12:30:00+00:00 Microbot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting https://ml.globenewswire.com/media/346df7fb-c134-40c2-970a-39bcbaf974cd/small/mbot-logo-rgb-jpg.jpg https://www.andorrahealthwatch.com/article/905478648-heartflow-files-patent-infringement-lawsuit-against-cleerly Andorra Health Watch en PressRelease 2026-04-13T12:30:00+00:00 Heartflow Files Patent Infringement Lawsuit Against Cleerly https://ml.globenewswire.com/media/c6be111e-2f8e-4ac8-8fa8-310dbcbd6e15/small/25-1113-cmyk-hf-logo-positive-png.png https://www.andorrahealthwatch.com/article/905478660-inspira-begins-ame-technology-implementation-process-with-one-of-the-world-s-10-largest-u-s-based-companies Andorra Health Watch en PressRelease 2026-04-13T12:16:00+00:00 Inspira Begins AME Technology Implementation Process with One of the World's 10 Largest U.S. Based Companies https://ml.globenewswire.com/media/6a4eabfe-c9ec-40d1-87fc-6f0d8e6e408c/small/screenshot-2025-04-02-at-19-21-06-png.png https://www.andorrahealthwatch.com/article/905478477-chemed-corporation-announces-a-five-year-450-million-amended-and-restated-credit-agreement Andorra Health Watch en PressRelease 2026-04-13T12:15:00+00:00 Chemed Corporation Announces a Five-Year $450 Million Amended and Restated Credit Agreement https://ml.globenewswire.com/media/1ab951c0-8d76-40e0-bc65-ebeaa1731e66/small/chemed-corp-logo-600x400-jpg.jpg https://www.andorrahealthwatch.com/article/905474851-nanox-signs-distribution-agreement-with-digital-x-ray-imaging-to-expand-nanox-arc-adoption-in-arkansas Andorra Health Watch en PressRelease 2026-04-13T12:10:00+00:00 Nanox Signs Distribution Agreement with Digital X-Ray Imaging to Expand Nanox.ARC Adoption in Arkansas https://ml-eu.globenewswire.com/media/7a1764f8-84e3-4b28-ae23-9add5d57c378/small/nanox-logo-4-png.png https://www.andorrahealthwatch.com/article/905474794-veld-pharmaceuticals-gmbh-announces-collaboration-with-chiesi-farmaceutici-s-p-a-to-expand-access-to-rare-disease-therapies-across-africa Andorra Health Watch en PressRelease 2026-04-13T12:00:00+00:00 Veld Pharmaceuticals GmbH Announces Collaboration with Chiesi Farmaceutici S.p.A to Expand Access to Rare Disease Therapies Across Africa https://ml-eu.globenewswire.com/media/047cc83e-f777-4658-9d34-e499423ec123/small/logo-veld-png.png https://www.andorrahealthwatch.com/article/905474801-impact-biotech-presents-preliminary-data-from-phase-1-study-of-padeliporfin-vtp-in-la-pdac-at-sir-2026-and-provides-strategic-business-update Andorra Health Watch en PressRelease 2026-04-13T12:00:00+00:00 ImPact Biotech Presents Preliminary Data from Phase 1 Study of Padeliporfin VTP in LA-PDAC at SIR 2026 and Provides Strategic Business Update https://ml-eu.globenewswire.com/media/68762066-1fff-4065-af45-d18da25273cd/small/impact-biotech-logo-final-resized-jpg.jpg https://www.andorrahealthwatch.com/article/905474927-geron-announces-appointment-of-timothy-williams-as-executive-vice-president-chief-legal-officer-and-corporate-secretary Andorra Health Watch en PressRelease 2026-04-13T12:00:00+00:00 Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary https://ml.globenewswire.com/media/e184bb51-5636-436e-8964-15613f24ca1f/small/geron-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905474962-pacira-presents-real-world-data-on-exparel-showing-lower-total-healthcare-costs-in-outpatient-total-hip-and-knee-arthroplasty-procedures Andorra Health Watch en PressRelease 2026-04-13T12:00:00+00:00 Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures https://ml.globenewswire.com/media/3e502c92-e576-46b6-b602-a177ab0f5044/small/pacira-biosciences-tm-logo-rgb-v2025-300dpi-adj-png.png https://www.andorrahealthwatch.com/article/905474978-brainsway-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference Andorra Health Watch en PressRelease 2026-04-13T12:00:00+00:00 BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/ea01c8f7-39be-46d2-a8e0-bc05994f170e/small/brainsway-2021-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905474988-septerna-announces-initiation-of-phase-1-clinical-trial-of-sep-479-an-oral-small-molecule-pth1r-agonist-for-the-treatment-of-hypoparathyroidism Andorra Health Watch en PressRelease 2026-04-13T12:00:00+00:00 Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism https://ml.globenewswire.com/media/8c635733-2794-456f-9bc4-3b53908acba9/small/septernalogo-black-10x-jpg.jpg https://www.andorrahealthwatch.com/article/905475004-favorable-results-of-ovarian-cancer-study-presented-at-annual-society-of-gynecological-care-conference Andorra Health Watch en PressRelease 2026-04-13T12:00:00+00:00 Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference https://ml.globenewswire.com/media/7e828ef4-6c8f-4c94-b376-4e3749530fba/small/logo-jpg.jpg https://www.andorrahealthwatch.com/article/905475007-stryker-signs-definitive-agreement-to-acquire-amplitude-vascular-systems-to-add-next-generation-ivl-technology-to-peripheral-vascular-portfolio Andorra Health Watch en PressRelease 2026-04-13T12:00:00+00:00 Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio https://ml.globenewswire.com/media/c24fe8bd-9db6-4f42-8a52-06a4e1b673b5/small/stryker-logo2015-jpg.jpg https://www.andorrahealthwatch.com/article/905475009-praxis-to-showcase-essential3-the-first-positive-phase-3-program-in-essential-tremor-at-aan-2026 Andorra Health Watch en PressRelease 2026-04-13T12:00:00+00:00 Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026 https://ml.globenewswire.com/media/bff1e728-30ed-46c6-81e1-8bbc795929c0/small/01-primarylogo-color-bluex-100-jpg.jpg https://www.andorrahealthwatch.com/article/905475038-cvrx-reports-preliminary-first-quarter-2026-financial-results Andorra Health Watch en PressRelease 2026-04-13T12:00:00+00:00 CVRx Reports Preliminary First Quarter 2026 Financial Results https://ml.globenewswire.com/media/04c4feba-7841-4ac8-8ca5-6c03be383a0e/small/cvrx-outsmart-the-heart-logo-rgb-blue-png.png https://www.andorrahealthwatch.com/article/905475045-daraxonrasib-demonstrates-unprecedented-overall-survival-benefit-in-pivotal-phase-3-rasolute-302-clinical-trial-in-patients-with-metastatic-pancreatic Andorra Health Watch en PressRelease 2026-04-13T12:00:00+00:00 Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer https://ml.globenewswire.com/media/771b34d9-586d-435a-a976-ab0ab847571b/small/balanced-green-primary-logo-medium-1000px-png.png https://www.andorrahealthwatch.com/article/905475055-eupraxia-pharmaceuticals-to-present-at-upcoming-investor-conferences Andorra Health Watch en PressRelease 2026-04-13T12:00:00+00:00 Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences https://ml.globenewswire.com/media/0b2bbe4b-1cf9-402e-8ea6-22c0043f310a/small/eupraxia-color-med-res-01-jpg.jpg https://www.andorrahealthwatch.com/article/905475064-akebia-therapeutics-announces-first-participants-dosed-in-phase-1-clinical-trial-of-akb-9090 Andorra Health Watch en PressRelease 2026-04-13T12:00:00+00:00 Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png https://www.andorrahealthwatch.com/article/905475065-catheter-precision-announces-accepted-publication-in-leading-european-medical-journal Andorra Health Watch en PressRelease 2026-04-13T12:00:00+00:00 Catheter Precision Announces Accepted Publication in Leading European Medical Journal https://ml.globenewswire.com/media/cb9f10dc-be78-4c7c-a235-81bfdd77f03c/small/catheterlogo-jpg.jpg https://www.andorrahealthwatch.com/article/905474987-nervgen-pharma-to-participate-in-the-h-c-wainwright-hcw-home-series-and-the-2026-bloom-burton-co-healthcare-investor-conference Andorra Health Watch en PressRelease 2026-04-13T11:45:00+00:00 NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference https://ml.globenewswire.com/media/bb42d0ef-06b6-4b90-8389-ca991092aa37/small/nervgen-logo-updated-globenewswire-png.png https://www.andorrahealthwatch.com/article/905475034-with-brain-scan-volume-momentum-accelerating-firefly-makes-history-by-building-the-world-s-first-known-200-000-standardized-eeg-erp-depository Andorra Health Watch en PressRelease 2026-04-13T11:45:00+00:00 With Brain Scan Volume Momentum Accelerating, Firefly Makes History by Building the World’s First Known 200,000+ Standardized EEG/ERP Depository https://ml.globenewswire.com/media/cd317e6a-730f-4537-a096-9b724abb964e/small/firefly-png.png https://www.andorrahealthwatch.com/article/905470717-allogene-therapeutics-reports-interim-futility-analysis-from-pivotal-alpha3-trial-showing-58-3-mrd-clearance-with-cemacabtagene-ansegedleucel Andorra Health Watch en PressRelease 2026-04-13T11:30:00+00:00 Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL https://ml.globenewswire.com/media/87e8712c-0741-409f-9942-c91b31e7c5e1/small/allogene-png.png https://www.andorrahealthwatch.com/article/905470753-vireo-growth-announces-california-retail-joint-venture-with-glass-house-brands Andorra Health Watch en PressRelease 2026-04-13T11:30:00+00:00 Vireo Growth Announces California Retail Joint Venture with Glass House Brands https://ml.globenewswire.com/media/d01c0dca-8260-48c8-8ead-e09111cf57b5/small/vireo-horizontalllogolockup-01-png.png https://www.andorrahealthwatch.com/article/905470768-newly-published-u-s-expert-consensus-aligns-with-mediwound-s-strategy-for-chronic-wound-debridement Andorra Health Watch en PressRelease 2026-04-13T11:30:00+00:00 Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement https://ml.globenewswire.com/media/55509183-b8b9-4da4-ae63-92c83760b5d9/small/mdwd-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905470778-northstrive-biosciences-announces-u-s-arrival-of-el-32-working-cell-bank-and-initiation-of-manufacturing-optimization-for-dual-myostatin-assets Andorra Health Watch en PressRelease 2026-04-13T11:30:00+00:00 NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences https://ml.globenewswire.com/media/b1dabc1a-ea7b-49d8-a9cd-406fd48dd65b/small/logo-color-1-jpg.jpg https://www.andorrahealthwatch.com/article/905470800-palvella-therapeutics-appoints-john-d-doux-m-d-m-b-a-dermatologist-and-recognized-leader-in-rare-skin-diseases-to-board-of-directors Andorra Health Watch en PressRelease 2026-04-13T11:30:00+00:00 Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors https://ml.globenewswire.com/media/83fd569b-5e6c-46ad-882a-6430f8ab755a/small/palvella-2025-logo-new-jpg.jpg https://www.andorrahealthwatch.com/article/905470793-gelatide-drops-investigated-2026-report-what-consumers-should-verify-before-buying Andorra Health Watch en PressRelease 2026-04-13T11:23:50+00:00 Gelatide Drops Investigated (2026 Report) What Consumers Should Verify Before Buying https://ml.globenewswire.com/Resource/Download/984a2986-fdd3-4fe6-80f2-312f9d1cbc94/image2.png https://www.andorrahealthwatch.com/article/905467090-from-milestone-to-momentum-kraig-biocraft-leadership-travels-to-south-east-asia-following-record-setting-1-3-metric-ton-recombinant-spider-silk Andorra Health Watch en PressRelease 2026-04-13T11:05:00+00:00 From Milestone to Momentum: Kraig Biocraft Leadership Travels to South East Asia Following Record-Setting 1.3 Metric Ton Recombinant Spider Silk Cocoon Production Cycle https://ml.globenewswire.com/media/3cf5ab91-0822-460b-bb13-17447941c84a/small/kblb-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905466754-oxb-launches-fast-track-offering-for-aav-and-lentiviral-vector-platforms-accelerating-viral-vector-development-and-manufacture Andorra Health Watch en PressRelease 2026-04-13T11:00:00+00:00 OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture https://ml-eu.globenewswire.com/media/3e905c0a-b28c-4981-ac57-745647779ad9/small/oxb-new-logo-png.png https://www.andorrahealthwatch.com/article/905466795-eclipse-life-sciences-completes-enrollment-in-phase-2-study-evaluating-ec-104-for-diabetic-macular-edema-dme Andorra Health Watch en PressRelease 2026-04-13T11:00:00+00:00 Eclipse Life Sciences Completes Enrollment in Phase 2 Study Evaluating EC-104 for Diabetic Macular Edema (DME) https://ml.globenewswire.com/media/3ed9dd28-ed00-4f7d-b5b9-1180c2c99262/small/eclipse-logo-png.png https://www.andorrahealthwatch.com/article/905466931-soleo-health-opens-new-ambulatory-infusion-center-in-louisville-kentucky Andorra Health Watch en PressRelease 2026-04-13T11:00:00+00:00 Soleo Health Opens New Ambulatory Infusion Center in Louisville, Kentucky https://ml.globenewswire.com/media/b3c4bcdc-fa25-4f50-8b81-09f13e80a008/small/soleo-logo-1024-x-1024-png.png https://www.andorrahealthwatch.com/article/905466947-nrx-pharmaceuticals-nasdaq-nrxp-announces-appointment-of-glenn-tyson-as-the-company-s-first-chief-commercial-officer Andorra Health Watch en PressRelease 2026-04-13T11:00:00+00:00 NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer https://ml.globenewswire.com/media/d879f1ff-d5d7-48d7-9731-c881b469d873/small/nrx-logo-300dpi-png.png https://www.andorrahealthwatch.com/article/905466972-kymera-therapeutics-announces-u-s-fda-fast-track-designation-for-kt-621-a-first-in-class-oral-stat6-degrader-for-the-treatment-of-moderate-to Andorra Health Watch en PressRelease 2026-04-13T11:00:00+00:00 Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma https://ml.globenewswire.com/media/4d3d3283-c57d-401e-9e1b-53f17e22d76b/small/kymera-logo-rgb-denim-marigold-high-res-png.png https://www.andorrahealthwatch.com/article/905466973-spyre-announces-potential-best-in-class-spy001-part-a-induction-results-from-skyline-trial-in-moderate-to-severe-ulcerative-colitis-patients Andorra Health Watch en PressRelease 2026-04-13T11:00:00+00:00 Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients https://ml.globenewswire.com/media/bc26a912-b583-43c6-8423-55a4ba2bf4bd/small/spyre-logo-horizontal-full-color-rgb-583px-300ppi-jpg.jpg https://www.andorrahealthwatch.com/article/905466986-ocular-therapeutix-announces-additional-positive-week-52-data-from-landmark-sol-1-phase-3-trial-of-axpaxli-in-wet-amd Andorra Health Watch en PressRelease 2026-04-13T11:00:00+00:00 Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905467081-imagenebio-announces-30-million-private-placement Andorra Health Watch en PressRelease 2026-04-13T11:00:00+00:00 ImageneBio Announces $30 Million Private Placement https://ml.globenewswire.com/media/ccccc30d-a51c-48d7-9aec-6b542240c611/small/imagene-logo-green-jpg.jpg https://www.andorrahealthwatch.com/article/905466794-ani-pharmaceuticals-announces-the-launch-of-carbamazepine-extended-release-capsules Andorra Health Watch en PressRelease 2026-04-13T10:50:00+00:00 ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules https://ml.globenewswire.com/media/24d1d851-9075-4d6e-b22c-0c23a5ef0b36/small/ani-logo-png.png https://www.andorrahealthwatch.com/article/905467025-leanzene-gummies-examined-2026-consumer-focused-breakdown-of-ingredients-claims-label-transparency Andorra Health Watch en PressRelease 2026-04-13T10:47:40+00:00 Leanzene Gummies Examined: 2026 Consumer-Focused Breakdown of Ingredients, Claims & Label Transparency https://ml.globenewswire.com/Resource/Download/e7b8402e-d943-467a-8865-1fec7f5629cc/image2.png https://www.andorrahealthwatch.com/article/905463063-regeneron-and-telix-announce-strategic-radiopharma-collaboration Andorra Health Watch en PressRelease 2026-04-13T10:30:00+00:00 Regeneron and Telix Announce Strategic Radiopharma Collaboration https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.andorrahealthwatch.com/article/905463143-telix-and-regeneron-announce-strategic-radiopharma-collaboration Andorra Health Watch en PressRelease 2026-04-13T10:30:00+00:00 Telix and Regeneron Announce Strategic Radiopharma Collaboration https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png https://www.andorrahealthwatch.com/article/905459654-prosomnus-receives-fda-class-ii-clearance-for-rpmo2-osa-device Andorra Health Watch en PressRelease 2026-04-13T10:00:00+00:00 ProSomnus® Receives FDA Class II Clearance for RPMO2 OSA Device https://ml.globenewswire.com/media/333d9b0e-92b8-4e8b-ab32-6689f4113578/medium/prosomnus-rpmo2-osa-device-system.jpg